Subscribe
aramadourian_flagshippioneering
18 July 2018

LSIPR 50 2018: The entrepreneurial bug

Since its founding in 2000, Flagship Pioneering has set up and fostered the development of more than 100 scientific ventures, resulting in $20 billion in aggregate value, more than 500 issued patents, and more than 50 clinical trials for novel therapeutic agents.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
A guide for life sciences entrepreneurs
22 December 2021   Small companies face the same long product cycles and upfront costs as the big players but have different IP challenges, explains Chad Shear of Fish & Richardson.


Editor's picks

In-house with Bayer: ‘Focus on quality early and stay close to inventors’
Europe
In-house with Bayer: ‘Focus on quality early and stay close to inventors’
15 July 2025

Editor's picks

Europe
In-house with Bayer: ‘Focus on quality early and stay close to inventors’
15 July 2025
Europe
UKIPO rejects Boehringer’s SPC for horse inhaler
8 July 2025
Europe
‘We created law’: G1/24 and the creation of the ‘diamond standard’
3 July 2025
Americas
Bankruptcy judge approves $305m sale of genetics testing company
1 July 2025
Americas
A step too far? Why Stewart’s approach is dividing opinion
24 June 2025
Europe
Diverging in the detail: UPC local divisions and Court of Appeal take different paths
19 June 2025

More on this story

Big Pharma
A guide for life sciences entrepreneurs
22 December 2021   Small companies face the same long product cycles and upfront costs as the big players but have different IP challenges, explains Chad Shear of Fish & Richardson.

More on this story

Big Pharma
A guide for life sciences entrepreneurs
22 December 2021   Small companies face the same long product cycles and upfront costs as the big players but have different IP challenges, explains Chad Shear of Fish & Richardson.

More features

AstraZeneca suffers defeat over $7bn diabetes patent
US firm Brownstein nabs five from Crowell ‘at pivotal moment’
American Regent secures rare PI win in Hatch-Waxman dispute
Explainer: ARIPO’s role in Plant Variety Protection
J&J sues over schizophrenia drug generic following patent victory
Chicago firm Much Shelist adds partner with ‘entrepreneurial mindset’
Startups toolkit: Why investors want more than patents
Kilpatrick adds ‘seasoned litigator’ as trademark partner